$OSCR

Blackley Richard Scott sold $202K of OSCR

Blackley Richard Scott (Chief Financial Officer) sold 8,977 shares of Oscar Health, Inc. (OSCR) at $22.45 ($0.20M total) on 2026-06-02 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Blackley Richard Scott
Published Jun 4, 2026, 8:15 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 4, 2026, 8:19 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$OSCR
Neutral
medium confidence
Mentioned
$OSCR
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$OSCRNeutralLow
01

Why it matters

The disclosed sale adds a datapoint on insider activity but does not, by itself, indicate a new corporate event like earnings, guidance, or a deal.

02

Market read

Traders may monitor insider activity, but 10b5-1 structure typically limits immediate fundamental inference.

03

What to watch

The filing doesn’t reveal the broader context (e.g., total planned sales, tax-related liquidity needs, or whether other insiders are buying).

Relevance 6/10Novelty 6/10Timing: After-hours/filing update (Form 4 filed 2026-06-04)

Background

This is an SEC Form 4 insider transaction disclosure for Oscar Health, reporting an officer’s open-market sale executed under a pre-arranged Rule 10b5-1 plan.

Company-level read

Ticker impact

$OSCRNeutralMedium confidence
Context

Oscar Health CFO sold 8,977 shares in an open-market transaction under a pre-arranged 10b5-1 plan, disclosed via SEC Form 4.

Expected impact

Limited near-term impact; any reaction is likely small and fades unless accompanied by other catalysts.

Evidence & confidence

The filing provides a specific sale datapoint (date, shares, price) but no accompanying fundamental change; 10b5-1 typically reduces interpretive weight.

Market effects

Minimal—single-company insider transaction with no stated sector-wide development.

None indicated.

None indicated.

Counterpoint

Even with 10b5-1, repeated insider selling can coincide with valuation concerns; traders may still fade rallies if selling cadence accelerates.

Key entities

  • Oscar Health, Inc.

    Subject of the Form 4 insider transaction disclosure.

  • Blackley Richard Scott

    Chief Financial Officer who sold shares.

Related articles

$OSCRMed

Oscar Health Q2 Earnings Call Highlights

Oscar Health (OSCR) reported Q2 SG&A ratio at a record low 14.2%, down 450 bps YoY, citing expense discipline and AI initiatives. It received a final 2025 CMS risk-adjustment report about $160M favorable, fully recognized in Q2, and initial 2026 report based on four months of claims. Management expects higher churn in H2 and stable MLR seasonally.

$OSCRMedAI 8/10

Oscar Health (OSCR) Q2 2026 Earnings Call Transcript

Oscar Health (OSCR) reported Q2 2026 revenue of $4.9B, up 70% year over year, and net income of $362M. Effectuated membership rose to 2.96M, and medical loss ratio improved to 79.2%. Management reiterated full-year revenue guidance of $18.7B to $19.0B and raised earnings from operations guidance to $500M to $700M, citing disciplined pricing and favorable prior-period reserves, while noting potential higher churn from CMS eligibility verification.

$OSCRMed

GoodRx and Oscar Health Tout Tech as Consumer Needs Change

GoodRx reported Q2 revenue of $200.4M, down 1%, and raised its full-year outlook, citing a projected 70% revenue increase from Pharma Direct. Oscar Health reported first-half 2026 results with revenue up 70% to $4.9B and record profitability, attributing gains to its AI platform and “Oswal” tools. Both cited shifting consumer insurance needs.

$OSCRMed

Oscar Health, Inc. Q2 2026 Earnings Call Summary

Oscar Health, Inc. reported record first-half profitability with $1 billion net income and improved medical loss ratio, citing disciplined pricing and favorable utilization. The company raised 2026 earnings from operations guidance to $500 million to $700 million, with full-year MLR expected at 81.5% to 82.5% and SG&A ratio 15.6% to 16.1%. It highlighted AI tools and CMS program integrity reviews.